5
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Submit your digital health research with an established publisher
      - celebrating 25 years of open access

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Comprehensive App That Improves Tuberculosis Treatment Management Through Video-Observed Therapy: Usability Study

      research-article
      , MPH, MD 1 , , MPH, MD 1 , , MPH, MD 1 , 2 , 3 , , MD, PhD 1 , , MPH, MD 1 , , MD 1 , , MPH, MD 1 , , MD 1 , , MD, PhD 1 ,
      (Reviewer), (Reviewer)
      JMIR mHealth and uHealth
      JMIR Publications
      tuberculosis, management, video-observed therapy, directly observed therapy, mobile phone

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Treatment of pulmonary tuberculosis (TB) requires at least six months and is compromised by poor adherence. In the directly observed therapy (DOT) scheme recommended by the World Health Organization, the patient is directly observed taking their medications at a health post. An alternative to DOT is video-observed therapy (VOT), in which the patients take videos of themselves taking the medication and the video is uploaded into the app and reviewed by a health care worker. We developed a comprehensive TB management system by using VOT that is installed as an app on the smartphones of both patients and health care workers. It was implemented into the routine TB control program of the Nanshan District of Shenzhen, China.

          Objective

          The aim of this study was to compare the effectiveness of VOT with that of DOT in managing the treatment of patients with pulmonary TB and to evaluate the acceptance of VOT for TB management by patients and health care workers.

          Methods

          Patients beginning treatment between September 2017 and August 2018 were enrolled into the VOT group and their data were compared with the retrospective data of patients who began TB treatment and were managed with routine DOT between January 2016 and August 2017. Sociodemographic characteristics, clinical features, treatment adherence, positive findings of sputum smears, reporting of side effects, time and costs of transportation, and satisfaction were compared between the 2 treatment groups. The attitudes of the health care workers toward the VOT-based system were also analyzed.

          Results

          This study included 158 patients in the retrospective DOT group and 235 patients in the VOT group. The VOT group showed a significantly higher fraction of doses observed ( P<.001), less missed observed doses ( P<.001), and fewer treatment discontinuations ( P<.05) than the DOT group. Over 79.1% (186/235) of the VOT patients had >85% of their doses observed, while only 16.4% (26/158) of the DOT patients had >85% of their doses observed. All patients were cured without recurrences. The VOT management required significantly ( P<.001) less median patient time (300 minutes vs 1240 minutes, respectively) and transportation costs (¥53 [US $7.57] vs ¥276 [US $39.43], respectively; P<.001) than DOT. Significantly more patients (191/235, 81.3%) in the VOT group preferred their treatment method compared to those on DOT (37/131, 28.2%) ( P<.001), and 92% (61/66) of the health care workers thought that the VOT method was more convenient than DOT for managing patients with TB.

          Conclusions

          Implementation of the VOT-based system into the routine program of TB management was simple and it significantly increased patient adherence to their drug regimens. Our study shows that a comprehensive VOT-based TB management represents a viable and improved evolution of DOT.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities

          Poor medication adherence may increase rates of loss to follow-up, disease relapse and drug resistance for individuals with active tuberculosis (TB). While TB programmes have historically used directly observed therapy (DOT) to address adherence, concerns have been raised about the patient burden, ethical limitations, effectiveness in improving treatment outcomes and long-term feasibility of DOT for health systems. Digital adherence technologies (DATs)—which include feature phone–based and smartphone-based technologies, digital pillboxes and ingestible sensors—may facilitate more patient-centric approaches for monitoring adherence, though available data are limited. Depending on the specific technology, DATs may help to remind patients to take their medications, facilitate digital observation of pill-taking, compile dosing histories and triage patients based on their level of adherence, which can facilitate provision of individualised care by TB programmes to patients with varied levels of risk. Research is needed to understand whether DATs are acceptable to patients and healthcare providers, accurate for measuring adherence, effective in improving treatment outcomes and impactful in improving health system efficiency. In this article, we describe the landscape of DATs that are being used in research or clinical practice by TB programmes and highlight priorities for research.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.

            Tuberculosis has reemerged as an important public health problem, and the frequency of drug resistance is increasing. A major reason for the development of resistant infections and relapse is poor compliance with medical regimens. In Tarrant County, Texas, we initiated a program of universal directly observed treatment for tuberculosis. We report the effect of the program on the rates of primary and acquired drug resistance and relapse among patients with tuberculosis. We collected information on all patients with positive cultures for Mycobacterium tuberculosis in Tarrant County from January 1, 1980, through December 31, 1992. Through October 1986, patients received a traditional, unsupervised drug regimen. Beginning in November 1986, nearly all patients received therapy under direct observation by health care personnel. A total of 407 episodes in which patients received traditional treatment for tuberculosis (January 1980 through October 1986) were compared with 581 episodes in which therapy was directly observed (November 1986 through December 1992). Despite higher rates of intravenous drug use and homelessness and an increasing rate of tuberculosis during this 13-year period, the frequency of primary drug resistance decreased from 13.0 percent to 6.7 percent (P < 0.001) after the institution of direct observation of therapy, and the frequency of acquired resistance declined from 14.0 percent to 2.1 percent (P < 0.001). The relapse rate decreased from 20.9 percent to 5.5 percent (P < 0.001), and the number of relapses with multidrug-resistant organisms decreased from 25 to 5 (P < 0.001). The administration of therapy for M. tuberculosis infection under direct observation leads to significant reductions in the frequency of primary drug resistance, acquired drug resistance, and relapse.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Global Epidemiology of Tuberculosis.

              Tuberculosis (TB) was the underlying cause of 1.3 million deaths among human immunodeficiency virus (HIV)-negative people in 2016, exceeding the global number of HIV/acquired immune deficiency syndrome (AIDS) deaths. In addition, TB was a contributing cause of 374,000 HIV deaths. Despite the success of chemotherapy over the past seven decades, TB is the top infectious killer globally. In 2016, 10.4 million new cases arose, a number that has remained stable since the beginning of the 21th century, frustrating public health experts tasked to design and implement interventions to reduce the burden of TB disease worldwide. Ambitious targets for reductions in the epidemiological burden of TB have been set within the context of the Sustainable Development Goals (SDGs) and the End TB Strategy. Achieving these targets is the focus of national and international efforts, and demonstrating whether or not they are achieved is of major importance to guide future and sustainable investments. This article reviews epidemiological facts about TB, trends in the magnitude of the burden of TB and factors contributing to it, and the effectiveness of the public health response.
                Bookmark

                Author and article information

                Contributors
                Journal
                JMIR Mhealth Uhealth
                JMIR Mhealth Uhealth
                JMU
                JMIR mHealth and uHealth
                JMIR Publications (Toronto, Canada )
                2291-5222
                July 2020
                31 July 2020
                : 8
                : 7
                : e17658
                Affiliations
                [1 ] Department of Tuberculosis Control and Prevention Shenzhen Nanshan Centre for Chronic Disease Control Shenzhen China
                [2 ] Pathogenomique Mycobacterienne Integree Institut Pasteur Paris France
                [3 ] Laboratorio de Genética Molecular Instituto Venezolano de Investigaciones Cientificas Caracas Venezuela
                Author notes
                Corresponding Author: Shengyuan Liu liushenglb@ 123456126.com
                Author information
                https://orcid.org/0000-0002-9047-1142
                https://orcid.org/0000-0003-3010-0945
                https://orcid.org/0000-0002-0480-0860
                https://orcid.org/0000-0002-1899-802X
                https://orcid.org/0000-0002-7923-324X
                https://orcid.org/0000-0002-9858-5638
                https://orcid.org/0000-0002-1338-8652
                https://orcid.org/0000-0002-5273-7157
                https://orcid.org/0000-0001-5494-7660
                Article
                v8i7e17658
                10.2196/17658
                7428914
                32735222
                d9fb5b36-3320-46f4-93ed-4bcb12f422c8
                ©Xujun Guo, Yarui Yang, Howard E Takiff, Minmin Zhu, Jianping Ma, Tao Zhong, Yuzheng Fan, Jian Wang, Shengyuan Liu. Originally published in JMIR mHealth and uHealth (http://mhealth.jmir.org), 31.07.2020.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR mHealth and uHealth, is properly cited. The complete bibliographic information, a link to the original publication on http://mhealth.jmir.org/, as well as this copyright and license information must be included.

                History
                : 1 January 2020
                : 10 March 2020
                : 23 April 2020
                : 3 June 2020
                Categories
                Original Paper
                Original Paper

                tuberculosis,management,video-observed therapy,directly observed therapy,mobile phone

                Comments

                Comment on this article